461 results about "Proteinoid" patented technology

The invention provides a KRAS G12D protein degradation agent and application thereof in medicine, and particularly provides a compound with a structure as shown in a formula (I) and application of a stereoisomer or a prodrug molecule containing the compound or pharmaceutically acceptable salt of the compound as medicine. The compound can degrade KRAS G12D protein in a targeted manner through a ubiquitin-proteasome way, so that the compound can be used for treating indications mediated by abnormal expression of the KRAS G12D protein. Wherein each group in the formula (I) is defined in the specification. # imgabs0 #

The invention provides an anti-human serum albumin nano antibody and application thereof, and belongs to the technical field of antibodies. The invention provides an anti-human serum albumin nano antibody HSA-32 with relatively high affinity, and the anti-human serum albumin nano antibody HSA-32 is subjected to humanized transformation, so that three obtained humanized anti-human serum albumin nano antibodies can be used for reducing the immunogenicity of the HSA-32 and improving the immunogenicity of the HSA-32; and high specificity and high affinity of combination with the human serum albumin and stability and solubility of the antibody are maintained. The anti-human serum albumin nano antibody can be used for separation, purification and detection of human serum albumin and separation and purification of polypeptide, protein or antibody drugs fused with the anti-human serum albumin nano antibody. Meanwhile, the anti-human serum albumin nano-antibody can effectively prolong the half-life period of polypeptide, protein and antibody drugs fused with the anti-human serum albumin nano-antibody, and can be used for developing long-acting polypeptide, protein or antibody drugs.

The present disclosure provides proteins useful for preventing, treating, inhibiting and / or eliminating infestation and infection of plants caused by various phytopathogenic pests, as well as formulations comprising such proteins, polynucleotides encoding such proteins, organisms expressing such proteins, and methods for preparing such proteins. And methods of using such proteins, formulations, polynucleotides, and organisms in agricultural and other effort areas.

The invention discloses a phytophthora plant pathogenic oomycete histone lysine methyl transfer protein as well as a coding gene and application thereof. Wherein the phytophthora sojae histone lysine methyltransferase KMT3-1 is as shown in a sequence 2 in the specification, and the phytophthora sojae histone lysine methyltransferase KMT3-1 is as shown in a sequence 2 in the specification; the coding gene is shown as a sequence 1. Experiments prove that the KMT3-1 protein plays an important role in the growth and development process of phytophthora sojae, specifically, after the protein is deleted, the growth rate of phytophthora hyphae is slowed down, the sporangium yield is remarkably reduced, the release of zoospores is stopped, the oospore yield is reduced, the pathogenicity is reduced, and the like. Corresponding histone methyltransferase inhibitors have different degrees of activity on typical plant pathogenic oomycetes such as phytophthora sojae, phytophthora capsici and phytophthora infestans. The gene provided by the invention has great application potential in the aspect of preventing and controlling the crop epidemic diseases caused by phytophthora plant pathogenic oomycetes, and a novel bactericide developed on the basis of the protein as an action target has important practical significance in controlling the occurrence and prevalence of the crop epidemic diseases caused by phytophthora.

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing) comprising the proteins or fusion proteins of the invention, or nucleic acid molecules encoding them. The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention.

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof, which have better BRD4 inhibition and degradation effects as a drug, and can be used for preparing drugs related to BRD4 inhibition and degradation. And preventing and / or treating related diseases. # imgabs0 #

The invention belongs to the field of medical chemistry, and particularly discloses a protein tyrosine phosphatase inhibitor, a pharmaceutical composition and application of the protein tyrosine phosphatase inhibitor, and the protein tyrosine phosphatase inhibitor is a compound shown in a general formula (I) or pharmaceutically acceptable salt of the compound. The invention also discloses a method for using the protein tyrosine phosphatase inhibitor to treat cancers, metabolic diseases and other related diseases. # imgabs0 #

The invention discloses arginine methyltransferase protein from phytophthora plant pathogenic oomycetes as well as a coding gene and application thereof. The arginine methyltransferase protein provided by the invention is as shown in sequences 6-8; the coding gene is shown in sequences 1-3. Experiments prove that the protein disclosed by the invention plays an important role in growth, development and pathopoiesis processes of typical phytophthora plant pathogen oomycete phytophthora capsici, and after the protein is deleted or the expression level is reduced, the growth rate of phytophthora capsici hyphae is reduced, the sporangium yield is reduced, the number of zoospore is reduced, the pathogenicity is reduced and the like. Corresponding arginine methyltransferase inhibitors have different degrees of activity on typical plant pathogenic oomycetes such as phytophthora capsici, phytophthora sojae and phytophthora infestans. The gene provided by the invention has great application potential in the aspect of preventing and controlling the crop epidemic diseases caused by phytophthora plant pathogenic oomycetes, and a novel bactericide developed based on the protein as an action target has important practical significance in controlling the occurrence and prevalence of the crop epidemic diseases caused by phytophthora.

The present disclosure provides proteins useful for preventing, treating, suppressing and / or eliminating infestations and infections of plants by various phytopathogenic pests, as well as formulations comprising such proteins, polynucleotides encoding such proteins, organisms expressing such proteins, and methods of using such proteins, formulations, polynucleotides and organisms in agriculture and other fields of endeavor.

The invention provides a protein toxicity prediction method and system based on sequence information. The method comprises the following steps: acquiring a plurality of protein sequences from a protein database; performing feature calculation on all the protein sequences to obtain six types of protein feature vectors; splicing the six types of feature vectors according to columns to obtain a first feature vector; performing dimension reduction screening on the first feature vector to obtain a second feature vector of the target dimension; training a neural network model based on graph attention by using the second feature vector, and taking the trained neural network model as a protein toxicity prediction model; and inputting the new protein sequence into the protein toxicity prediction model to obtain a toxicity prediction result output by the protein toxicity prediction model. The method can adapt to different types of protein sequences, and the protein toxicity is accurately predicted through the learned universal sequence mode.

The invention discloses a pharmaceutical composition for promoting angiogenesis and tissue regeneration and application thereof. The pharmaceutical composition of the present invention comprises an acidic secretory protein rich in cysteine, a disaccharide chain proteoglycan, and an XV-type collagen alpha1 chain. The biological material system loaded with the three types of proteins can promote angiogenesis, and can improve the tissue regeneration efficiency of bone, cartilage and skin defect areas.

The invention belongs to the technical field of genetic engineering and molecular breeding, and particularly relates to application of TaHPPD protein in regulation and control of wheat stripe rust resistance. The TaHPPD protein disclosed by the invention can be used for weakening the accumulation of reactive oxygen species (ROS) and cell necrosis reaction caused by CNL protein NLRMro and reducing ion leakage. A TaHPPD gene in wheat is knocked out through a gene editing technology, a TaHPPD knockout (TaHPPD-KO) wheat material is obtained, and wheat with wheat stripe rust resistance is obtained. The result of the embodiment shows that the TaHPPD-KO wheat plant shows obvious resistance compared with the control Fielder. The TaHPPD protein can be used for regulating and controlling the stripe rust resistance of wheat, and can be used for cultivating stripe rust resistant wheat.

The invention provides an NSD protein degradation agent and application thereof, and particularly provides a compound with a structure as shown in a formula (I) or pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like in a targeted ubiquitination manner, so that the compound can be used for treating indications related to abnormal expression of the proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, GSPT1 and the like. # imgabs0 #

The invention discloses an ADF protein from phytophthora as well as a coding gene and application thereof. According to the present invention, the PsADF protein provided by the present invention is the protein represented by sequences 2 and 5 in Phytophthora sojae (Phytophthora sojae); the coding gene is shown as a sequence 3 and a sequence 4. Tests prove that the protein provided by the invention plays an important role in the growth and development process of phytophthora sojae, specifically, after the 64-site mutation of the key amino acid functional site of the protein, the sporangium abnormality and zoospore quantity of the phytophthora sojae are reduced, and the pathogenicity is reduced. The protein provided by the invention has very high application value in control of epidemic disease occurrence and epidemic caused by phytophthora, and provides a molecular target for research and development of novel bactericides in the future. The corresponding ADF inhibitors have different degrees of activity on typical plant pathogenic oomycetes such as phytophthora sojae, phytophthora capsici and phytophthora infestans. The protein provided by the invention has great application potential in the aspect of preventing and controlling the crop epidemic diseases caused by phytophthora plant pathogenic oomycetes, and a novel bactericide developed based on the protein as an action target has important practical significance in controlling the occurrence and prevalence of the crop epidemic diseases caused by phytophthora.

The present invention relates to novel DLL3 / CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise an alpha-L-iduronidase (IDUA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat MPS I.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

The invention belongs to the technical field of microorganisms, discloses a strain of pseudomonas putida and application of the strain of pseudomonas putida as fish probiotics, and particularly discloses a strain of pseudomonas putida. The invention provides a symbiotic pseudomonas putida CD separated from fish, and the strain has relatively strong fat utilization capability, can generate a plurality of beneficial extracellular metabolites, can promote metabolism of fish lipids, carbohydrates and proteins and weight gain, and also can improve the iron content and hemoglobin content in fish tissues. The pseudomonas putida strain CD disclosed by the invention has good biological safety, and has a wide development prospect in the aspect of application as fish probiotics.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain with binding specificity for soluble mesothelin or membrane-bound mesothelin. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer in a mammal, including a human.

The present disclosure provides compositions and methods for targeting neoantigens, for example, to treat or prevent cancer. The disclosed embodiments include binding proteins, such as T cell receptors, that bind to the neoantigen: HLA complex. The binding protein further comprises a construct comprising a fusion protein of the CD95 extracellular domain and the CD137 intracellular signaling domain (Fas-41BB), and a CDS coreceptor alpha or beta chain. The disclosed binding proteins are highly sensitive to antigens and are capable of inducing activation of host T cells at low concentrations of peptide antigens. In certain embodiments, binding proteins of the present disclosure (i) have no alloreactivity, substantially no alloreactivity, and / or low risk of alloreactivity, to amino acid sequences from human proteomes and / or (ii) to human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapy for the treatment of various cancers.

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and / or compositions to the subject.

The invention provides a palladium-carbon catalyst as well as a preparation method and application thereof. The palladium-carbon catalyst comprises an activated carbon carrier and palladium loaded on the activated carbon carrier, and the mass fraction of the palladium is 0.2-0.9% based on 100% of the mass of the activated carbon carrier; the content of the palladium is distributed in a protein-like manner, less than 5% of the palladium is distributed on a surface layer of 0-5 microns, 80-95% of the palladium is distributed on a protein-like layer of 5-50 microns, and the rest of the palladium is distributed on an inner layer of 50-200 microns. The palladium-carbon catalyst provided by the invention is used for a crude terephthalic acid refining reaction, and has the characteristics of palladium loss reduction, high catalyst activity and long service life.

This disclosure relates methods for expanding γδ T cells. More specifically, the disclosure relates to methods of expanding γδ T cells that have an eliminated or reduced expression of endogenous MHC Class I molecules, by expressing a single-chain fusion HLA Class I protein. In some embodiments, the endogenous B2M gene of the γδ T cells is disrupted. In some embodiments, the single-chain fusion HLA Class I protein includes at least a portion of B2M protein and at least a portion of HLA-E heavy chain.

The present invention provides an NSD protein degradation agent and a use thereof. Specifically, the present invention provides a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer or prodrug molecule thereof. The compound can degrade proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, and GSPT1 via target ubiquitination, and therefore can be used to treat indications related to abnormal expression of proteins such as NSD2, NSD1, NSD3, c-MYC, KLK3 / PSA, AR, NKX3.1, and GSPT1.

The invention discloses a TLP1-like gene molecular marker related to cotton verticillium wilt resistance and application of the TLP1-like gene molecular marker, and belongs to the field of biotechnology application. The promoter of the TLP1 protein gene TLP1-like has two haplotypes, the promoter sequence of the haplotype 1 is SEQ ID NO.5, and the genomic sequence of the haplotype 2 is SEQ ID NO.6. The invention also discloses a method for preparing the TLP1 protein gene TLP1-like promoter of the TLP1 protein gene TLP1-like promoter of the TLP1 protein gene. Compared with the haplotype 1, the haplotype 2 has an SV insertion of 2623 bp at a-899 bp position of an ATG upstream promoter region of a TLP1-like gene, so that the expression quantity of the TLP1-like gene is reduced. An InDel functional marker capable of remarkably distinguishing the haplotype 1 and the haplotype 2 is further developed. Compared with the haplotype 1, the haplotype 2 has a remarkable advantage in the aspect of improving the verticillium wilt resistance of the cotton, and the silent haplotype 1 cotton plant TLP1-like remarkably improves the resistance of the cotton to verticillium dahliae. The haplotype 2 has important effects and application prospects in screening cotton disease-resistant materials and cultivating cotton high-resistance varieties.

The preparation method of the double-protein yoghourt comprises the following steps: fermenting mixed emulsion by adopting zymophyte; the main components of the mixed emulsion are plant-based milk and animal milk; the zymophyte comprises Weissella fusiformis and yoghurt zymophyte. The obtained double-protein yoghurt contains animal-derived and plant-derived proteins at the same time, animal and plant protein complementation is achieved, dietary fibers lacked in the animal-derived yoghurt are provided, and more comprehensive nutrition is provided for the human body. The obtained double-protein yoghurt can still show stable texture without adding a stabilizer, has no layering phenomenon, is good in coagulability, does not separate out whey in a storage period, and is a healthy food which is free of additives and rich in nutrition; the obtained double-protein yogurt is free of bad flavors such as fishy smell, high in sensory score and good in commercial prospect.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of cow milk allergen(s), specifically T cell epitopes for T cells responsive to one or more cow milk peptides or proteins comprising, consisting of, or consisting essentially of: one or more peptides or proteins selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein comprising one or more amino acid sequences selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such protein(s) or peptide(s).